Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.03
- Piotroski Score 6.00
- Grade Buy
- Symbol (KMDA)
- Company Kamada Ltd.
- Price $5.87
- Changes Percentage (0.26%)
- Change $0.02
- Day Low $5.80
- Day High $5.89
- Year High $6.53
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 06/13/2013
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 02/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $20.00
- High Stock Price Target $20.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.23
- Trailing P/E Ratio 22
- Forward P/E Ratio 22
- P/E Growth 22
- Net Income $8.28 M
Income Statement
Quarterly
Annual
Latest News of KMDA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ...
The company reported strong growth for Kedrab and Cytogam products, with an estimated market share of 40-50%. InnovAte trial enrollment is at 50%, with ongoing discussions with the FDA....
By Yahoo! Finance | 1 week ago -
Kamada Ltd. (KMDA): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
The article discusses Kamada Ltd. and its position among cheap pharmaceutical stocks. It highlights the evolving pharma industry, the rise of biotechnology, and factors influencing firm valuations. Ka...
By Yahoo! Finance | 2 months ago
